Azacitidine and Valproic Acid Plus Carboplatin in Patients With Ovarian Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

October 31, 2012

Study Completion Date

October 31, 2012

Conditions
Solid Tumors
Interventions
DRUG

Azacitidine

75 mg/m\^2 Subcutaneous Injection or by vein Daily for 5 Days.

DRUG

Valproic Acid

40 mg/kg by mouth Daily for 7 days.

DRUG

Carboplatin

AUC 2 by vein on Days 3 and 10 over 60 Minutes.

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER